# Meet Bloomwell, The Telehealth Company Growing Germany’s $900 Million Cannabis Industry > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/germany-telehealth-cannabis-market-growth/ > **Published:** 2026-03-20T19:48:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:42:57-04:00 > **Clinical Summary:** Explore Germany telehealth cannabis market growth with Bloomwell, a leader in digital health cannabis platforms ensuring clinical standards and patient safety. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic TelemedicineInternational PolicyHealthcare DeliveryClinical StandardsMarket Access Why This Matters Germany’s telehealth cannabis market represents a significant regulatory model for evidence-based [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) in Europe. The growth of structured telehealth platforms like Bloomwell demonstrates how digital health infrastructure can scale specialized [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) while maintaining clinical oversight and patient safety standards. Clinical Summary Bloomwell operates as a telehealth platform facilitating [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) consultations and prescriptions in Germany’s regulated $900 million cannabis market. The company appears to focus on connecting patients with cannabis-trained physicians through digital channels, following Germany’s [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) framework established in recent years. This model represents an evolution of telemedicine specifically adapted for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), addressing both access barriers and the need for specialized clinical expertise in cannabinoid therapeutics. Dr. Caplan’s Take “Telehealth cannabis platforms succeed when they maintain rigorous clinical standards rather than simply facilitating access. The real test for companies like Bloomwell will be whether they can deliver meaningful patient outcomes and advance the clinical science, not just capture market share in a growing industry.” Clinical Perspective Clinicians should evaluate telehealth cannabis platforms based on their commitment to evidence-based protocols, physician training standards, and patient outcome tracking. Patients considering such services should ensure their providers have specific cannabis medicine training and follow established clinical guidelines rather than simply offering prescriptions through convenient digital interfaces. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Meet%20Bloomwell%2C%20The%20Telehealth%20Company%20Growing%20Germany%27s%20%24900%20Million%20Cannabis%20I...%20%40drcaplan&url=https%3A//www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Meet%20Bloomwell%2C%20The%20Telehealth%20Company%20Growing%20Germany%27s%20%24900%20Million%20Cannabis%20I...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/](https://www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance level of this cannabis news update?](#What_is_the_clinical_relevance_level_of_this_cannabis_news_update) - [What type of cannabis-related development is being discussed?](#What_type_of_cannabis-related_development_is_being_discussed) - [What key areas does this cannabis news cover?](#What_key_areas_does_this_cannabis_news_cover) - [Why should healthcare providers pay attention to this update?](#Why_should_healthcare_providers_pay_attention_to_this_update) - [Is this considered urgent or routine clinical information?](#Is_this_considered_urgent_or_routine_clinical_information) - [Related](#Related) ## FAQ #### What is the clinical relevance level of this cannabis news update? This update has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This classification is reserved for emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related development is being discussed? This appears to be cannabis news from CED Clinic focusing on policy and healthcare delivery aspects. The update relates to emerging findings or developments in the cannabis medicine field that have notable clinical significance. #### What key areas does this cannabis news cover? The news covers four main areas: telemedicine, international policy, healthcare delivery, and clinical standards. These topics suggest the update involves regulatory or practice changes affecting how cannabis medicine is delivered to patients. #### Why should healthcare providers pay attention to this update? The “Notable Clinical Interest” designation indicates this development could impact clinical practice or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Healthcare providers should monitor these emerging findings as they may influence treatment protocols or regulatory compliance requirements. #### Is this considered urgent or routine clinical information? While marked as “New” and worthy of close monitoring, this falls under “Notable Clinical Interest” rather than urgent breaking news. It represents important emerging information that should be tracked but doesn’t require immediate action. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Meet Bloomwell, The Telehealth Company Growing Germany’s $900 Million Cannabis Industry”, “url”: “https://www.forbes.com/sites/willyakowicz/2026/03/20/meet-bloomwell-the-telehealth-company-growing-germanys-900-million-cannabis-industry/”, “datePublished”: “2026-03-20T16:03:14Z”, “about”: “meet bloomwell telehealth company growing germany”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New Report: UK and Germany Medical Cannabis Markets Both Double in 2025](https://cedclinic.com/uk-germany-medical-cannabis-markets-double-2025/) An insightful report detailing the rapid expansion of medical cannabis markets in the UK and Germany, highlighting regulatory and market trends. [Read the full report](https://cedclinic.com/uk-germany-medical-cannabis-markets-double-2025/) [Swiss Canton St Gallen Launches Large-Scale Cannabis Study](https://cedclinic.com/swiss-canton-st-gallen-launches-large-scale-cannabis-study/) Discover how Switzerland's St Gallen is advancing [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) with a large-scale study, contributing to evidence-based cannabis medicine. [Explore the study](https://cedclinic.com/swiss-canton-st-gallen-launches-large-scale-cannabis-study/) [Will Medicinal Cannabis Help My Mental Health? Here Are the Evidence and the Risks](https://cedclinic.com/medicinal-cannabis-demand-mental-health-soars-evidence-risks/) A balanced review of medicinal cannabis effects on mental health, discussing clinical evidence and potential risks for patients. [Learn more](https://cedclinic.com/medicinal-cannabis-demand-mental-health-soars-evidence-risks/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).